AVITA Medical, Inc.

NasdaqCM:RCEL Rapport sur les actions

Capitalisation boursière : US$236.5m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

AVITA Medical Bilan de santé

Santé financière contrôle des critères 3/6

AVITA Medical has a total shareholder equity of $23.9M and total debt of $41.0M, which brings its debt-to-equity ratio to 171.4%. Its total assets and total liabilities are $87.8M and $63.9M respectively.

Informations clés

171.4%

Ratio d'endettement

US$40.99m

Dette

Ratio de couverture des intérêtsn/a
Argent liquideUS$54.06m
Fonds propresUS$23.92m
Total du passifUS$63.91m
Total des actifsUS$87.83m

Mises à jour récentes de la santé financière

Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Jun 18
Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Recent updates

AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 11
AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jul 18
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Jun 18
Is AVITA Medical (NASDAQ:RCEL) A Risky Investment?

Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

Apr 12
Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding

AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

Feb 02
AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39%

The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

Oct 20
The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32%

Avita Medical appoints James Corbett as CEO

Sep 29

AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal

Sep 12

Avita's burn therapy Recell gets insurance coverage in Japan following approval

Sep 01

AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M

Aug 11

AVITA Medical Is Interesting, But Not Just Yet

Dec 21

AVITA Medical reports preliminary Q2 revenue in-line with consensus

Jan 12

AVITA: COVID-19's Impact

Nov 17

Analyse de la situation financière

Passif à court terme: RCEL's short term assets ($73.0M) exceed its short term liabilities ($13.8M).

Passif à long terme: RCEL's short term assets ($73.0M) exceed its long term liabilities ($50.1M).


Historique et analyse du ratio d'endettement

Niveau d'endettement: RCEL has more cash than its total debt.

Réduire la dette: RCEL's debt to equity ratio has increased from 0% to 171.4% over the past 5 years.


Bilan


Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: RCEL has less than a year of cash runway based on its current free cash flow.

Prévisions de trésorerie: Insufficient data to determine if RCEL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Découvrir des entreprises saines